bioRxiv Science⌕ Search

bioRxiv · 10.1101/2025.04.17.649382

Real-world testing of the durability claims of a commercially available spray-on surface biocide

Abstract

Self-disinfecting biocidal surfaces have been proposed as a solution to prevent infections caused by the transmission of microorganisms from frequently touched surfaces in hospitals and other settings. For example, surface anchoring quaternary ammonium salt (SAQAS)-based biocides are purported to maintain their antimicrobial potency for up to 30 days and are available as spray-on formulations. We tested the 30-day potency claim of a commercially available spray-on SAQAS-based biocide ("SAQAS-A") under "real-world" conditions in a microbiology laboratory where regular cleaning is routine. To do this, we determined the background microbial burden on high-traffic floor areas, routinely used bench areas, frequently touched handles, and glass surfaces for 30 days before and after applying SAQAS-A. Experiments were repeated three times, and data was analysed using two Generalised Linear Mixed Models. We observed that for >80% of bench samples, the number of viable bacteria recovered was below the highest acceptable level of 2.5 CFU/cm2, with minimal reduction in CFU recovery observed after SAQAS-A treatment. In contrast, the number of floor and glass samples in which the microbial burden exceeded 2.5 CFU/cm2 was greater after biocide application (12.7 and 73%, respectively) than before (4.8 and 37%, respectively). Analysis of all data using two statistical models confirmed that the application of SAQAS-A had no antimicrobial effect. In conclusion, our results indicate that SAQAS-A was ineffective in preventing surface contamination over 30 days in a real-world scenario where routine cleaning occurs. ImportanceWe tested the claim that a commercially available spray-on biocide could protect surfaces from microbial contamination for 30 days. In the presence of routine disinfection, we found that spray-on applications of the surface anchoring quaternary ammonium salt-based biocide did not protect frequently touched surfaces in a working microbiology research lab for up to 30 days. Our data show that users of this type of product should be aware of the limitations of manufacturers claims of "continued protection", and manufacturers should consider formulations that more reliably attach to surfaces. Similarly, regulatory and consumer protection agencies should provide clear guidance for companies wishing to make durability and longevity claims for biocidal surface applications.

Source connections

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Saseendran Nair, S., Cavadino, A., Swift, S., Wiles, S.. 2025-04-17. Real-world testing of the durability claims of a commercially available spray-on surface biocide. https://doi.org/10.1101/2025.04.17.649382

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

pTRIP, a novel integration plasmid for Listeria monocytogenes

In the past decades, several tools to genetically modify the human pathogen Listeria monocytogenes were developed. Here, we constructed a new integrative plasmid system for L. monocytogenes named pTRIP, for treB insertion plasmid. pTRIP is a vector which stably integrates into the treB locus of the wild type EGD-e. This locus encodes the sole trehalose-specific EIIB and EIIC component of a phosphotransferase system. Successful integration leads to the disruption of treB and thus, to an inability of the resulting L. monocytogenes strains to grow on trehalose as sole carbon source. Due to integration through double homologous recombination, it is the first integrative system which does not require antibiotic selection pressure. To assess functionality of the pTRIP system, prfA and its native promoter region were integrated into the treB locus of a {Delta}prfA strain. Complementation was confirmed in 78% of the isolated clones, indicating successful integration of prfA into the treB locus. We further constructed derivatives of pTRIP harboring the constitutive Pp60 (pTRIP1) and the inducible Prha (pTRIP2) promoter to further expand application possibilities. Microscopic analyses confirmed the functionality of both promoter constructs and showed dose-dependent induction for Prha. pTRIP is an efficient tool for stable gene expression as well as functional studies and expands genetic modification possibilities for L. monocytogenes.

microbiology↗

A rational design strategy and validation for protease-resistant fusion-inhibitor antiviral peptides

Peptide-based fusion inhibitors are promising pharmaceuticals in the fight against enveloped viruses relying on membrane fusion for host infection. However, peptide therapeutic applications have long been hindered by their poor stability in vivo. Here, we discovered that peptide inhibitors with the wildtype sequence of the heptad repeat 2 (HR2) domain of the SARS-CoV-2 spike protein are efficiently cleaved by Transmembrane Protease, Serine 2 (TMPRSS2), a key protease involved in the SARS-CoV-2 virus-cell fusion pathway. We then identified the corresponding cleavage sites and designed three protease-resistant peptides using ranking based on deep mutational scanning and natural occurrence. The three candidates all exhibit inhibitory activity in a cell-cell fusion assay. A high-resolution cryo-EM structure of the top candidate, HR2-NHN, bound to its HR1 target reveals the molecular basis for its potent activity. The top candidate of the cell-based screening assay significantly improved efficacy relative to the wildtype peptide when administered 12 h before infection in both an authentic virus-cell infection assay and a mouse assay. More broadly, our results suggest that the design strategies for protease-resistant peptides could be applied to a broad spectrum of other enveloped viruses and pave the way for the development of safe, prophylactic antivirals that can be administered before exposure.

microbiology↗

Host soluble inositol phosphate signaling promotes coronavirus replication

Coronaviruses rely extensively on host pathways for replication, making host-directed therapies an attractive strategy for broad-spectrum antivirals with reduced risk of viral resistance. Here we identify the host soluble inositol phosphate pathway as a previously unrecognized dependency for coronavirus infection. Genetic or pharmacologic inhibition of several kinases in this pathway markedly suppresses replication of both alpha- and betacoronaviruses, while increasing pathway activity promotes viral replication. We developed UNC7844, a potent multi-target inhibitor of these kinases, which reduces coronavirus replication by more than four orders of magnitude in cultured cells and suppresses coronavirus infection in mice. Mechanistically, UNC7844 suppresses inositol (pyro)phosphates production, disrupts phosphoinositide homeostasis, and impairs late endosomal dynamics, blocking early post-entry steps required for viral genome release and replication. Together, our findings establish the soluble inositol (pyro)phosphate pathway as an important regulator of coronavirus infection and highlight its inhibition as a promising host-directed antiviral strategy.

microbiology↗